Experimental drug combo targets Hard-to-Treat lung cancer
NCT ID NCT04922658
First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time
Summary
This phase II trial tests the drug surufatinib, either alone or combined with the chemotherapy vinorelbine, in people with advanced non-small cell lung cancer who have already tried at least two prior treatments. The goal is to see if these treatments can slow tumor growth or shrink tumors. Participants take the drugs by mouth daily, and the study measures how long they live without the cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- surufatinib, an oral drug that blocks blood vessel growth to tumors, sometimes combined with vinorelbine, a chemotherapy drug
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced lung cancer who have run out of standard therapies.
- What could go wrong
- This is a small, early-phase study without a comparison group, so results may not confirm real benefit. Side effects from the drug combination could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Guangzhou, Guangdong, 510095, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smartphone app ease the burden of advanced lung cancer?
- Breath of discovery: simple test may sniff out lung cancer
- Acupuncture with a jolt: could needles shield nerves from chemo?
- AI could predict who lives longer after lung cancer immunotherapy
- Lung cancer drug tislelizumab under Real-World scrutiny in 440-Patient european study
- New combo therapy takes on advanced cancers